In the News
ESMO Daily Reporter
June 27, 2024
Recent data indicate a role of immunotherapy for tumours with high levels of microsatellite instability, especially in the neoadjuvant setting.
Mirror
June 14, 2024
The combination of two drugs used to boost immune response could shrink tumours in 60 per cent of patients, according to the new research by Anglia Ruskin University.
BioCentury
May 31, 2024
Several immuno-oncology mechanisms on display at this year’s ASCO help the field inch closer to solving one of cancer immunotherapy’s biggest problems: achieving efficacy in cold solid tumors.
The Pharmaletter
May 9, 2024
Part of a growing trend in the industry, Ligand Pharmaceuticals (Nasdaq: LGND) has inked a royalty financing agreement with immunology company Agenus (Nasdaq: AGEN).